The subchronic toxicity of tripelennamine hydrochloride was determined to provide data for selecting dose levels for a 2-year study in mice. Male and female B6C3F1 mice were administered the drug in their feed at dose levels of 0,150,300,600,1200, and 2400 ppm (calculated as free amine) for 14 days or 0, 300, 600, 1200, 2400, and 4800 ppm for 90 days. Little toxicity was observed in the 14-day study. In the 90-day study, final body weights of males and females of the 4800 ppm groups were reduced 14% and 4%, respectively. Clinical observations and necropsy findings were unremarkable in the 90-day study. Decreased heart weight/brain weight ratios in males and increased liver weight/brain weight ratios in females were seen at dose levels as low as 600 ppm. Histologically, changes consisting of cytomegaly, karyomegaly, and cytoplasmic vacuolization of the liver, mild to severe cytomegaly and necrosis of parotid salivary gland acinar cells, and a mild degree of vacuolar degeneration of the bronchial epithelium of the lung were observed. The results indicate that an oral dose level of 2000 ppm tripelennamine would not be life-shortening in male or female B6C3FZ mice in a 2-year study.
T extensively in cream preparations for various skin irritations and in tablet or elixir form for allergies, rhinitis, and cold remedies with expectorants.(') The acute toxicity of tripelennamine was reviewed by Haley more than 40 years ago"' and again more re~ently.'~' More details of previous studies on tripelennamine are presented in a recent report on subchronic studies of tripelennamine in Fischer 344 rats.'4) An oral LD,, of 200 2 14 mg/kg was reported in the mouse.'') Tripelennamine was mutagenic in Euglena gracilis'" but not in Salmonella or Escherichia coli.@) Tripelennamine was found to induce unscheduled DNA synthesis in primary hepatocyte cultures in three different laboratories. "-91 Tripelennamine is structurally similar to methapyrilene, an antihistamine shown to be a potent liver carcinogen in the rat.'") Although methapyrilene was found to be carcinogenic in the rat, it failed to produce tumors in hamsters and guinea pigs'"' and was only mildly hepatotoxic in an 8-month study in mice."" Before this study, there was little information on the toxicity of tripelennamine in the mouse. This study was designed to determine the subchronic toxicity of tripelennamine in B6C3F, mice and provide data for selecting appropriate dose levels for a 2-year carcinogenesis study in this hybrid strain of mouse. 
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MATERIALS AND METHODS
Tripelennamine hydrochloride (CAS No. 154-69-8) was obtained from Ciba Pharmaceutical Co., Summit, NJ, and administered as an admixture in Purina 5010 Rodent Laboratory Chow as described previously.(4' For comparison with other studies, the dose levels were expressed as parts per million (ppm) of the free amine rather than as the hydrochloride.
Male and female B6C3F, mice were produced for the study by crossing female C57BL/6N and male C3H/Hen MTV-mice. Animals were started on experiment when approximately 37 days old. Mice were maintained four per cage on hardwood chips in polycarbonate cages covered with filter bonnets under specific pathogen free (SPF) housing. Food and water were provided ad libitum, and cages were changed weekly, with new bedding, food, and water being provided. In the 14-day study, groups of 6 mice per sex were maintained on feed containing dose levels of 0, 150,300,600, 1200, and 2400 ppm tripelennamine. In the 90-day study, groups of 12 animals per sex were administered dose levels of 0,300,600, 1200,2400, and 4800 pprn tripelennamine. The mice were killed by CO, anesthesia and necropsied, and selected organs were weighed. Tissues were processed for histologic examination as described previously for
In the 90-day study, all animals in the control and highest dose groups were examined histologically. Treatment-related changes were identified in the liver, parotid salivary gland, and lung. Consequently, these organs were examined in all dose groups.
RESULTS
14-Day study
All animals in the 14-day study survived until they were killed on day 15. Weight gain was reduced in both males and females in the 1200 pprn and 2400 pprn groups, with final body weights being reduced 8.1% and 7.6% group.
Body weight gain of male B6C3F, mice administered tripelennamine for 90 days. ti = 12 animals per compared to controls in males and females, respectively ( Table I ) . In contrast with the reduced weight gain by animals in the two highest dose groups, these groups had an apparent increased food consumption (not shown) of approximately 25% compared to controls. Clinical observations during the study and gross observations at necropsy were unremarkable in the 14-day study. Histologically, the only lesions believed to be treatment related were one male and two female mice in the 2400 ppm groups exhibiting scattered small foci of hepatic necrosis.
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90-Day study
All mice in the 90-day study survived until they were killed. Tripelennamine produced a dose-related decrease in weight gain in both males and females (Figs. 2 and 3) . A small decrease in final body weight (Table 2 ) was found in all treated groups except females in the 1200 ppm group. The patterns of food consumption by males and females were similar, and only that of males is presented (Fig. 4) . An apparent increase in food consumption was found in the 2400 ppm and 4800 ppm groups, even though these groups gained less weight than controls.
There were no consistent treatment-related clinical observations during the 90-day study, and no significant gross lesions were observed at necropsy. A number of statistically significant treatment-related changes in organ weights were observed ( Table 3 ). The most notable were decreased heart weight/brain weight ratios in males and increased liver weighthain weight ratios in females at 600, 1200, and 2400 ppm tripelennamine.
Treatment-related histologic changes were found in the liver (Table 4) , parotid salivary gland (Table 5) , and Food consumption by male B6C3F, mice administered tripelennamine for 90 days. n = three cages of (1) or increase (I) with p < 0.05 shown in parentheses. bronchial mucosa (Table 6 ). Liver lesions in males consisted of cytomegaly alone, either mild or moderate, and cytomegaly along with karyomegaly, varying in degree from mild to moderate to severe. The lesion or combined lesions occurred most frequently in the highest dose groups. Only one female in the 4800 pprn group had cytomegaly without the karyomegaly. Females in the 1200 pprn and 2400 ppm dose groups also had an increased incidence of cytoplasmic vacuolization of the liver. Changes in the acinar cells of the parotid salivary gland were subtle and consisted of mild to severe cytomegaly in which the cytoplasm of the affected cells was basophilic and granular. There was also an increased incidence of individual cell necrosis of the acinar cells in the treated groups. The most notable lesion found in the lungs of treated mice was degeneration of the bronchial mucosa. The lesions were very subtle and present mainly in the secondary bronchi.
MALES
DISCUSSION
Tripelennamine produced little toxicity in either the 14-day or 90-day study. There were no treatment-related mortalities in either study up to dose levels of 4800 ppm, and reductions in weight gain were minimal. With respect to weight gain, tripelennamine was slightly more toxic to males than females, with final body weights in the 90-day study being reduced 14.2% and 3.9% in 4800 pprn dose groups of males and females, respectively. The apparent increased food consumption by the highest dose groups could not be explained in light of the reduced weight gain. One possibility is that this level of tripelennamine in the food is unpalatable, and there was excess food spillage by this group due to food scattering. This effect also has been observed with other antihistamine^."^) Several organ weights were affected by tripelennamine administration in the 90-day study. Liver weights, expressed as a ratio to brain weights, were increased in females in the 600, 1200, and 2400 pprn groups, but there was little correlating histopathology found. In contrast, male mice exhibited a high degree of cytomegaly and karyomegaly of the liver in the treated groups, but the organ weights were not different from controls. There were other organ weights affected, but they were all decreases in the higher dose groups, which probably reflected the reduced body weights in those groups. One exception might be the treatment-related reduction in heart weight, which was observed in males in all but the lowest dose group. The changes observed histologically in the salivary glands were difficult to interpret. The acinar cells exhibited mild to severe cytomegaly, with the cytoplasm being basophilic and granular. There were also cases of individual cell necrosis that varied from a few cells to more than 30 necrotic cells per high field (40X). These changes also have been observed with other antihistamines in rat^"^.'^' and mice(") and may only represent a physiologic response to the antihistamines by this organ. Antihistamines are known to have anticholinergic activity that inhibits salivation and produces a dryness of the mouth."" The inhibitory effect of antihistamines on salivation could explain the cytomegaly and the changes in staining characteristics, but the cell necrosis is more difficult to explain. Although secretory glands, such as the salivary gland, are known to be susceptible to autolysis during killing of the animal and tissue preparation, the dose-response observed with the cell necrosis could not be explained. These results suggest the need for chronic studies to determine the effects of long-term exposure of tripelennamine on the parotid salivary gland.
The lung bronchial mucosa also is highly susceptible to autolysis when not fixed and stained properly. However, the correlation of both incidence and severity of the lung lesion with the dose level of tripelennamine indicated that the lesion is treatment related. It is known that the atropinelike properties of the antihistamine inhibit secretion of cholinergically innervated glands and reduce ongoing secretion in the respiratory tree.(16) Thus, like the salivary gland, it is not clear whether tripelennamine has a direct effect on these secretory tissues or whether it, in some manner, predisposes these organs to degeneration and autolysis during preparation of the tissues for examination.
The lack of toxicity and the flatness of the final body weight curves made it difficult to chose a highest dose for a 2-year study in mice. Based on final body weights, a maximum tolerated dose (MTD) in which the final weight would not be reduced more than 10% was estimated to be approximately 2000 pprn for males and greater than the 4800 pprn tested in females. Considering the histologic changes, males exhibited a marked incidence in cytomegaly and karyomegaly in the liver at dose levels of 1200 ppm or greater. Females exhibited a marked increase in the incidence of cytoplasmic vacuolization at these same doses. Since the lesions were mild at dose levels below 2400 pprn and the reduction in final body weight was less than 10% at doses below 2400 ppm, it was concluded that a dose level of 2000 pprn tripelennamine would be tolerated without life shortening in a 2-year study in male or female B6C3F, mice.
